New Jersey A2020 prohibits pharmacists from substituting prescribed epilepsy drugs without prior notification and written consent from both the.
New Jersey A2020 aims to prevent pharmacists from substituting prescribed epilepsy drugs without prior notification to and written consent from both the prescribing physician and the patient. This bill addresses the unique challenges of managing epilepsy, where small variations in drug concentrations can lead to toxic effects or seizures. The legislation defines "anti-epileptic drug" and "epilepsy" and mandates that pharmacists cannot interchange these drugs without the necessary consents.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.